Search

Displaying results 1001 - 1010 of 4692 in total
  1. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the

  2. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. … This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.

  3. Drug

    Fosamprenavir

    go.drugbank.com/drugs/DB01319
    ApprovedInvestigational

    Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.

  4. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

  5. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    Testosterone undecanoate is the ester prodrug of testosterone and has a mid-chain fatty acid at the carbon 17β position. It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. T...

  6. Drug

    Samarium (153Sm) lexidronam

    go.drugbank.com/drugs/DB05273
    Approved

    The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. … Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical.

  7. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  8. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]

  9. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate can...

  10. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor